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OBJECTIVE—Islet amyloid, formed by aggregation of the -cell
peptide islet amyloid polypeptide (IAPP; amylin), is a patholog-
ical characteristic of pancreatic islets in type 2 diabetes. Toxic
IAPP aggregates likely contribute to the progressive loss of
-cells in this disease. We used cultured human islets as an ex
vivo model of amyloid formation to investigate whether suppres-
sion of proIAPP expression would inhibit islet amyloid formation
and enhance -cell survival and function.
RESEARCH DESIGN AND METHODS—Islets from cadaveric
organ donors were transduced with a recombinant adenovirus
expressing a short interfering RNA (siRNA) designed to suppress
human proIAPP (Ad-hProIAPP-siRNA), cultured for 10 days, and
then assessed for the presence of islet amyloid, -cell apoptosis,
and -cell function.
RESULTS—Thioflavine S–positive amyloid deposits were clearly
present after 10 days of culture. Transduction with Ad-hProIAPP-
siRNA reduced proIAPP expression by 75% compared with
nontransduced islets as assessed by Western blot analysis of islet
lysates 4 days after transduction. siRNA-mediated inhibition of
IAPP expression decreased islet amyloid area by 63% compared
with nontransduced cultured islets. Cell death assessed by
transferase-mediated dUTP nick-end labeling staining was de-
creased by 50% in transduced cultured human islets, associated
with a significant increase in islet insulin content (control, 100 
4 vs. Ad-siRNA, 153  22%, P  0.01) and glucose-stimulated
insulin secretion (control, 222  33 vs. Ad-siRNA, 285  21
percent basal, P  0.05).
CONCLUSIONS—These findings demonstrate that inhibition of
IAPP synthesis prevents amyloid formation and -cell death in
cultured human islets. Inhibitors of IAPP synthesis may have
therapeutic value in type 2 diabetes. Diabetes 57:3045–3055,
2008
Islet amyloid deposits are a pathological lesion of thepancreas in type 2 diabetes (1–3) formed by aggre-gation of islet amyloid polypeptide (IAPP; amylin)(4,5), a 37–amino acid hormone that is colocalized
with insulin in -cell granules and secreted along with
insulin in response to -cell secretagogues (6–8). Aggre-
gates of IAPP, including small oligomeric species, are
toxic to -cells (9–14) and likely play an important role in
the progressive loss of -cells in this disease. Despite
considerable study during the past decade, it is still not
well understood why soluble IAPP molecules form toxic
IAPP aggregates in type 2 diabetes. The presence of an
amyloidogenic amino acid sequence in the human IAPP
molecule (Gly-Ala-Iso-Leu-Ser [GAILS]) appears to be im-
portant but not sufficient for amyloid formation (2,3,15,16).
Because production and secretion of IAPP closely mimic
that of insulin, IAPP levels are elevated in conditions
associated with insulin resistance and hyperinsulinemia,
such as the early stages of type 2 diabetes (17). Elevated
IAPP production and secretion because of increased de-
mand for insulin along with defective trafficking and/or
processing of proIAPP associated with -cell dysfunction
have been implicated as two possible factors contributing
to aggregation of (pro)IAPP (i.e., proIAPP and its interme-
diate forms) in type 2 diabetes (2,3,16,18–23).
Studies performed using transgenic rodent models have
demonstrated a strong association between -cell expres-
sion of human IAPP and development of hyperglycemia
associated with loss of -cells (24–29). -Cell loss in these
models was attributed to the formation of toxic IAPP
aggregates as either small oligomeric species or amyloid
fibrils. Studies on human and nonhuman primates have
also demonstrated development of islet amyloid associ-
ated with -cell loss in type 2 diabetes (30,31). It is not
clear from these studies, however, whether IAPP aggre-
gation and amyloid formation is the cause or a conse-
quence of -cell dysfunction and death. In the present
study, we tested the hypothesis that suppression of
human IAPP expression would inhibit amyloid forma-
tion and enhance survival and/or function of human
islets. We and others have found that islet amyloid
forms rapidly in islets from transgenic mice with -cell
expression of human IAPP, and its formation is poten-
tiated by elevated glucose concentrations (23,32–35).
We used cultured human islets as an ex vivo model of
amyloid formation to investigate whether short interfer-
ing RNA (siRNA)-mediated suppression of endog-
enously expressed human proIAPP will enhance -cell
survival in human islets.
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FIG. 1. Inhibition of adenoviral-mediated expression of human proIAPP in COS-1 cells by siRNA enhances cell survival. A: COS-1 cells were
transduced with Ad-hProIAPP-EGFP (MOI 5; 2 h), incubated with fresh media (4 h) to allow recovery, and transfected with pSuper-hProIAPP-
siRNA (4 g; 4 h). Apoptotic cells were detected 96 h after transfection by double TUNEL (red) and Hoechst-33342 (blue) staining performed
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RESEARCH DESIGN AND METHODS
Thioflavine S, Hoechst-33342, dithizone, BSA, aprotinin, pepstatin A, phenyl-
methylsulphonyl fluoride, and leupeptin were obtained from Sigma-Aldrich
(Oakville, ON, Canada). Dulbecco’s modified Eagle’s medium (DMEM), RPMI-
1640, fetal bovine serum (FBS), Lipofectamine, OptiMEM buffer, gentamicin,
penicillin, and streptomycin were from Invitrogen Canada (Burlington, ON,
Canada). All electrophoresis chemicals were from Bio-Rad Laboratories
(Mississauga, ON, Canada).
Human islet cultures. Human islets isolated from male and female cadaveric
organ donors aged between 46 and 68 years were received from Human Islet
Isolation Centers at McGill University (Montreal, Canada) and the University
of Illinois (Chicago). Islets were maintained in CMRL culture medium
containing BSA, 11.1 mmol/l glucose, 50 units/ml penicillin, 50 g/ml strepto-
mycin, and 50 g/ml gentamicin at 37°C in a humid atmosphere of 95% air/5%
CO2.
Cell lines. COS-1 cells, a transformed monkey kidney cell line, and HEK293T
cells, a human embryonic kidney cell line, were obtained from the American
Type Culture Collection (Manassas, VA). COS-1 and HEK293T cells were
cultured in DMEM containing 11.1 and 22 mmol/l glucose supplemented with
10% FBS, 50 units/ml penicillin, and 50 g/ml streptomycin at 37°C in a humid
atmosphere of 95% air 5% CO2. INS-1 cells, used as a control in Western blot
analysis of IAPP expression in human islets, were maintained in culture as
previously described (23).
Antisera and recombinant adenoviruses for expression of human IAPP.
IgG-purified antibody (RGG-7323) to IAPP was obtained from Peninsula
Laboratories (Belmont, CA). Human IAPP antiserum was provided by Dr.
Anne Clark (University of Oxford, Oxford, U.K.). Adenovirus expressing a
human proIAPP–enhanced green fluorescent protein (EGFP) fusion chimera
with green fluorescent protein (GFP), Ad-hProIAPP-EGFP, was provided by
Dr. Christopher Rhodes (University of Chicago, Chicago, IL).
Generation of human proIAPP siRNA recombinant adenovirus. The
siRNA target spans from nucleotides 372 to 393 of the human IAPP mRNA
(accession number NM-000415). The sense (5-AG AGA GAG CCA CTG AAT
TA-3) and antisense (5-TAA TTC AGT GGC TCT CTC T-3) siRNA oligonu-
cleotides were designed and synthesized as described previously (36) with a
few modifications. Sense and antisense oligonucleotides were annealed in
salt/Tris/EDTA buffer and ligated into BglII/HindIII-linearized pSuper (Oligo-
Engine, Seattle, WA). The siRNA expression cassette was excised from the
pSuper-based clone with EcoRI-HindIII and ligated into EcoRI-HindIII–
linearized adenoviral shuttle vector, EH006. To create RNA interference
adenovirus by homologous recombination, EH006-derived shuttle vectors
were cotransfected with the adenoviral plasmid pjM17 into HEK293T cells.
The Ad-hProIAPP-siRNA generated was further amplified in HEK293T cells,
and cell lysates containing viral particles were purified using an adenoviral
purification kit from Vivascience (Hanover, Germany). This adenovirus is
predicted to express a short RNA hairpin that is further processed to the
bioactive siRNA in cells. An adenovirus expressing a random siRNA (Ad-Cont-
siRNA) (37) was used as a control.
Transfection and adenoviral transduction. COS-1 cells at 70% conflu-
ency were transduced with AdhProIAPP-EGFP (multiplicity of infection [MOI]
5) in DMEM (22 mmol/l glucose) for 2 h followed by 4 h incubation with fresh
medium to allow recovery. Cells were then transfected with 4 g pSuper-
siRNA or pSuper-siRNA-GFP (as transfection control) using Lipofectamine
and OptiMEM buffer (Invitrogen) for 4 h. Cells were incubated with fresh
medium for 36 h after transfection. For experiments on primary islet -cells,
islets isolated from cadaveric human donors (hand-picked, purity90%) were
cultured overnight to allow recovery from the isolation process and shipping.
Purity of islets was assessed by dithizone staining before transduction. Islets
were transduced with Ad-hProIAPP-siRNA (or Ad-Cont-siRNA as indicated in
figure legends) overnight, washed, and incubated with CMRL medium con-
taining 11.1 mmol/l glucose for 96 h after transduction. Culture medium was
changed every 2 days.
Glucose-stimulated insulin secretion. Human islets (50/well, three wells
per condition) were preincubated (1 h) in Krebs-Ringer bicarbonate buffer
(KRBB) containing 10 mmol/l HEPES (pH 7.4), 0.25% BSA, and 1.67 mmol/l
glucose (KRBB-G1.67) in 48-well plates at 37°C followed by a 1-h incubation
in KRBB containing either 1.67 mmol/l (basal insulin release) or 16.7 mmol/l
glucose to stimulate release of insulin. Incubation media were collected gently
and centrifuged (15,000g, 10 min, 4°C), and the supernatants were saved for
insulin immunoassays. Human islets in each well were centrifuged, and the
pellets were lysed in 100 l lysis buffer containing 1 mol/l HCl and 0.1% BSA.
Media and islet lysates were frozen at	20°C until assayed. Insulin levels were
measured using a human-specific insulin ELISA kit (EZHI-14K) from Linco
Research (St. Charles, MO).
Electrophoresis and immunoblotting. Human islets were lysed in 30 l
Nonidet P-40 lysis buffer as described previously (38). Aliquots of islet protein
(10 or 15 g) were electrophoresed on a polyacrylamide gel (using Tris-
Tricine buffer for IAPP) followed by immunoblot analysis for detection of
IAPP using antisera from Peninsula (7323; 1:100) or A. Clark (Oxford; 1:200)
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:1,000) for 1 h at
room temperature. Membranes were then washed and incubated with horse-
radish peroxidase–conjugated anti-rabbit (or anti-mouse for GAPDH) IgG
(Amersham, Baie d’Urfe, QC, Canada) diluted 1:5,000. Immunodetection was
performed using an enhanced chemiluminescence detection kit (Amersham).
Protein bands were analyzed by densitometry using Quantity One quantitation
analysis software.
Transferase-mediated dUTP nick-end labeling, thioflavine S, and im-
munostaining. To detect apoptotic cells, COS-1 cells were fixed in 4%
paraformaldehyde (PFA) in 0.1 mmol/l PBS (pH 7.5) for 20 min, permeabilized
with 0.5% Triton X-100 in PBS, and incubated with transferase-mediated dUTP
nick-end labeling (TUNEL) reaction mixture (Roche Diagnostics, Laval, QC,
Canada) for 1 h at 37°C and then stained with Hoechst-33342 for 10 min.
Human islets were fixed in 4% PFA, as described above, for 40 min. For double
insulin and thioflavine S staining, paraffin-embedded sections (5 m) were
blocked in 0.05 mol/l PBS plus 0.25% Triton X-100 containing 2% normal goat
serum (Vector Laboratories, Burlingame, CA), rinsed, and incubated with
guinea pig anti-insulin antibody (Dako, Carpinteria, CA) at a 1:100 dilution in
PBS:1% BSA at 4°C overnight, followed by incubation with Texas Red–
conjugated goat anti–guinea pig antibody (Jackson ImmunoResearch, West
Grove, PA) for 1 h (1:100) at room temperature. The slides were rinsed and
incubated in 0.5% thioflavine S solution for 2 min. For TUNEL assay, islet
sections were incubated with TUNEL reaction mixture for 30 min at 37°C
followed by DAPI staining (Vector) for detection of the nuclei. For double
insulin and glucagon immunostaining, after incubation with anti-insulin anti-
body, islet sections were incubated (1 h) with goat anti–guinea pig antibody
conjugated to the green fluorophore Alexa Fluor 488 (Molecular Probes,
Eugene, OR). Sections were then similarly incubated with rabbit anti-glucagon
antibody (Dako) and donkey anti-rabbit antibody conjugated with Texas Red
(1:100) (Jackson) for 1 h. For double insulin and TUNEL staining, islet
sections were incubated with TUNEL reaction mixture (Roche Diagnostics)
for 1 h at 37°C. Thioflavine S–positive area in paraffin sections of cultured
islets was determined as a percentage of total islet area using Image-Pro 6.2
(Media Cybernetics, Bethesda, MD). At least two different islet sections were
analyzed from each culture well, and all islets in each section (100 islets)
were included in the analysis.
Statistical analysis. Data are expressed as means  SE. Statistical analyses
were performed using one-way ANOVA followed by Newman-Keuls or Stu-
dent’s t test, as appropriate. P  0.05 was taken as significant. Data are
representative of a minimum of three independent experiments performed in
triplicate.
RESULTS
Suppression of adenoviral-mediated expression of
human proIAPP by siRNA in COS-1 cells prevents
(pro)IAPP-induced cell death. To test the efficiency of
the siRNA constructs to suppress proIAPP expression, we
used COS-1 cells transduced with an adenovirus encoding
a human proIAPP-EGFP fusion protein (Ad-hProIAPP-
EGFP) as an in vitro model for human proIAPP expres-
sion. Transduced COS-1 cells were then transfected with
pSuper-hProIAPP-siRNA. Transduction efficiency with Ad-
on nontransduced control cells (left), cells transduced with Ad-hProIAPP-EGFP alone (middle), or cells transduced with Ad-hProIAPP-EGFP and
transfected with pSuper-hProIAPP-siRNA (right). Transduction efficiency in cells transduced with Ad-hIAPP-EGFP, estimated by the number of
COS-1 cells expressing GFP 36 h after transduction, was >70%. Transfection efficiency estimated by the number of COS-1 cells expressing
pSuper-siRNA-EGFP was 60%. Note the higher number of TUNEL-positive cells in COS-1 cells expressing human proIAPP alone (middle)
compared with those expressing human proIAPP in the presence of siRNA (right). B: Quantification of TUNEL-positive COS-1 cells transduced
with Ad-hProIAPP-EGFP with or without transfection with pSuper-hProIAPP-siRNA. Data are presented as means  SE of three independent
experiments performed in triplicate (P < 0.01, one-way ANOVA). (Please see http://dx.doi.org/10.2337/db08-0485 for a high-quality digital
representation of this figure.)
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hProIAPP-EGFP, as assessed by detection of COS-1 cells
expressing GFP 36 h after transduction, was 70%. Trans-
fection efficiency with the siRNA construct was 60%, as
estimated by detection of fluorescence in COS-1 cells
transfected with pSuper-siRNA-GFP, a plasmid with a
similar construct that expresses GFP. As expected (23,39),
expression of fibrillogenic human proIAPP in COS-1 cells
resulted in an increase in the number of TUNEL-positive
(apoptotic) cells (Fig. 1), whereas adenoviral expression
of nonamyloidogenic rat proIAPP was not toxic (data not
shown). Transfection with pSuper-hProIAPP-siRNA mark-
edly decreased the number of GFP-expressing cells,
indicating effective suppression by the siRNA of the
expression of the proIAPP-EGFP fusion protein in cells
transduced with Ad-hProIAPP-EGFP. Interestingly, inhibi-
tion of adenoviral-mediated human proIAPP expression by
transfection with pSuper-hProIAPP-siRNA was associated
with a marked decrease in the number of apoptotic COS
cells (Fig. 1).
ProIAPP gene silencing in human islets by an siRNA-
expressing adenovirus. To determine whether suppres-
sion of IAPP synthesis will inhibit amyloid formation and
enhance survival of -cells, we generated an adenovirus to
deliver a specific human proIAPP siRNA (Ad-hProIAPP-
siRNA) into -cells in isolated human islets. The siRNA
construct that was found to provide the most effective
suppression of proIAPP in COS-1 cells (Fig. 1) was chosen
for generation of Ad-hProIAPP-siRNA as described in
RESEARCH DESIGN AND METHODS. Isolated human islets were
transduced with Ad-hProIAPP-siRNA or a control adeno-
virus expressing a random siRNA (Ad-Cont-siRNA) (37)
overnight (16 h) and cultured in CMRL with 11.1 mmol/l
glucose for up to 10 days. IAPP-immunoreactive forms
were detected by Western blot 10 days after transduction.
As expected, mature IAPP (4 kDa) was the major
IAPP-immunoreactive form detected in preculture isolated
human islets. Interestingly, after a 10-day culture, the
major detectable (pro)IAPP form in human islets was a
partially processed 6 kDa intermediate form (Fig. 2A),
suggesting that prolonged culture in elevated glucose
concentrations impairs proIAPP processing, in accor-
dance with a previous report (20). Transduction with
Ad-ProIAPP-siRNA reduced expression of human
(pro)IAPP by 75% compared with nontransduced cul-
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FIG. 2. Suppression of proIAPP expression in cultured human islets by transduction with Ad-hProIAPP-siRNA. Human islets were transduced with
Ad-hProIAPP-siRNA (MOI 20) or Ad-Cont-siRNA (20) and cultured in CMRL (11.1 mmol/l glucose) for 10 days. A: Western blot analysis was
performed on the human islet extracts (10 g) followed by immunoblot using human IAPP antibody. IAPP (4 kDa) was the predominant
IAPP-immunoreactive form in preculture human islets, whereas a partially processed form of proIAPP (6 kDa) was the major IAPP-
immunoreactive form in human islets after 10-day culture. IAPP-immunoreactive forms in INS-1 cells (30 g) are shown as control for different
(pro)IAPP molecular species (left lane). B: Densitometric analysis of immunoblots. Transduction with Ad-hProIAPP-siRNA reduced (pro)IAPP
immunoreactivity 75%. Results are presented as the percentage of IAPP-immunoreactive forms with (pro)IAPP immunoreactivity in
nontransduced cultured islets taken as 100%. Data are expressed as means  SE of three independent experiments. *Significantly different from
transduced islets (P < 0.01, ANOVA).
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FIG. 3. Suppression of proIAPP expression in human islets inhibits amyloid formation. A: Thioflavine S (light blue) and insulin (red) double
staining of paraffin-embedded human islet sections before culture and after 10-day culture with or without transduction with Ad-hProIAPP-
siRNA. Amyloid deposits were readily detectable in 10-day-cultured human islets, associated with areas of decreased insulin staining. Amyloid
formation was markedly reduced by siRNA-mediated suppression of proIAPP in transduced islets. B: Quantification of amyloid (thioflavine
S)-positive islet areas in transduced and nontransduced cultured human islets (day 10). siRNA-mediated inhibition of human proIAPP expression
resulted in a 63% decrease in islet amyloid area in transduced islets compared with nontransduced control islets (P < 0.01, Student’s t test).
(Please see http://dx.doi.org/10.2337/db08-0485 for a high-quality digital representation of this figure.)
L. MARZBAN AND ASSOCIATES
DIABETES, VOL. 57, NOVEMBER 2008 3049
FIG. 4. Prevention of proIAPP synthesis in cultured human islets by siRNA-mediated suppression of proIAPP reduces islet cell apoptosis. A:
Paraffin-embedded sections of human islets before culture and after 10-day culture with or without transduction with Ad-hProIAPP-siRNA (or
Ad-Cont-siRNA) were stained for TUNEL positivity (red) and Hoechst-33342 (blue). After 10-day culture, extensive TUNEL-positive staining was
observed in nontransduced cultured human islets (top right). siRNA-mediated suppression of proIAPP expression markedly reduced the number
of TUNEL-positive cells in 10-day-cultured human islets (bottom left). Transduction with Ad-Cont-siRNA did not have any significant effect on
the number of TUNEL-positive cells (bottom right). B: Quantification of the number of TUNEL-positive cells as a percentage of the total number
of cells in transduced cultured human islets. Results are expressed as means SE of three independent experiments (P< 0.01, one-way ANOVA).
(Please see http://dx.doi.org/10.2337/db08-0485 for a high-quality digital representation of this figure.)
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tured islets or islets transduced with Ad-Cont-siRNA (Fig.
2A and B). The degree of reduction of (pro)IAPP expres-
sion induced by Ad-hProIAPP-siRNA was dependent on
the viral MOI (data not shown); an MOI of 20 was found
empirically to be optimal and used in subsequent experi-
ments.
siRNA-mediated suppression of proIAPP expression
inhibits amyloid formation and apoptosis and pre-
serves -cells in cultured human islets. To investigate
the effects of suppression of proIAPP expression on
survival of cultured human islet cells, histological analysis
was performed on paraffin-embedded sections of human
islets transduced with Ad-hProIAPP-siRNA or Ad-Cont-
siRNA or left nontransduced and cultured for 10 days.
Thioflavine S staining revealed the presence of clearly
detectable amyloid deposits after 10-day culture of un-
treated human islets (Fig. 3A, top right), similar to those
observed in type 2 diabetic human pancreas, suggesting
that amyloid formation occurs very rapidly in cultured
human islets, as in transgenic human IAPP-expressing
mouse islets (23,32–35). Islets transduced with Ad-
hProIAPP-siRNA to inhibit proIAPP expression had a
marked reduction in visible amyloid (Fig. 3A, bottom left),
whereas those transduced with the control adenovirus
(Ad-Cont-siRNA) were indistinguishable from nontrans-
duced islets (Fig. 3A, bottom right). Quantification of
amyloid area in islet cultures confirmed that adenoviral
siRNA-mediated inhibition of IAPP expression reduced
amyloid formation by 60% (P  0.05; Fig. 3B).
Apoptotic islet cells were detected and quantified by
double TUNEL and DAPI nuclear staining. As expected,
preculture human islets had low levels of TUNEL-positive
cells (Fig. 4A, top left), but the number of apoptotic cells
was markedly increased after a 10-day culture (Fig. 4A, top
right). siRNA-mediated suppression of proIAPP expres-
sion decreased the proportion of apoptotic cells in human
islets cultured for 10 days by 50% (Fig. 4A, bottom left,
and B), whereas transduction with Ad-Cont-siRNA did not
have any detectable effect on islet cell death (Fig. 4A,
bottom right, and B).
Because DAPI staining does not distinguish between -
and non–-islet cells, we next evaluated whether -cell
apoptosis was inhibited by adenoviral siRNA-mediated
suppression of IAPP expression. To this end, we double
stained islet sections for insulin and TUNEL. Many insulin/
TUNEL double-positive islet cells were apparent in sections
of nontransduced cultured human islets (Fig. 5A, left). Al-
though insulin/TUNEL double-positive islet cells were also
observed in Ad-hProIAPP-siRNA transduced islets, these
appeared lower in frequency (Fig. 5A, right). A higher
magnification view of these cells revealed that they were
TUNEL positive and insulin positive (Fig. 5, bottom). Collec-
tively, these data suggest that inhibition of IAPP expression
in cultured human islets decreases -cell apoptosis.
Notably, many TUNEL-positive cells in cultured human
islets were found to be insulin negative (Fig. 5). Although
many of these cells may be non–-cells, we suspect that
the majority of TUNEL-positive, insulin-negative cells in
our islet cultures are -cells that have lost detectable
insulin staining while undergoing cell death. To evaluate
this possibility, we next double immunostained, for insulin
and glucagon, sections of cultured islets that had been
transduced with Ad-hProIAPP-siRNA or Ad-Cont-siRNA or
left untreated and quantified the ratio of - to 
-cells as a
measure of -cell–specific loss (Fig. 6). siRNA-mediated
inhibition of IAPP expression was associated with a 33%
increase in the ratio of - to 
-cells compared with
nontransduced islets (Fig. 6). Transduction with an Ad-
Cont-siRNA did not have any significant effect on the
-cell–to–
-cell ratio. These data demonstrate that inhibi-
tion of IAPP expression preserves -cells in cultured
human islets.
FIG. 5. siRNA-mediated suppression of human proIAPP expression decreases -cell apoptosis. Double immunostaining for insulin (green) and
TUNEL (red) of paraffin-embedded sections (5 m) of human islets after 10-day culture that were either nontransduced (left) or transduced
(right) with Ad-hProIAPP-siRNA (MOI 20). Double insulin/TUNEL-positive cells were observed in nontransduced and transduced human islet
cultures but were more frequent in cultures transduced to express human IAPP siRNA. Higher magnification view (insets a, b, and c) shows
insulin immunopositivity localized to cells with TUNEL-positive nuclei, demonstrating -cell apoptosis. TUNEL-positive cells that are insulin
negative were also frequently observed. (Please see http://dx.doi.org/10.2337/db08-0485 for a high-quality digital representation of this figure.)
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Inhibition of human proIAPP synthesis increases in-
sulin content and enhances -cell function in cul-
tured human islets. To determine whether siRNA-
mediated prevention of amyloid formation and islet cell
death enhances -cell function in cultured human islets,
we measured insulin content and glucose-stimulated insu-
lin secretion (GSIS) in human islets after 10-day culture.
Adenoviral siRNA-mediated inhibition of proIAPP synthe-
sis was associated with an increase in islet insulin content
and higher levels of insulin secretion after stimulation with
16.7 mmol/l glucose for 1 h (Fig. 7). Human islets trans-
duced with Ad-Cont-siRNA had insulin content and GSIS
that were similar to untreated controls (Fig. 7).
DISCUSSION
Progressive loss of islet -cell mass and function is a key
defect in type 2 diabetes, ultimately leading to -cell
failure. The decrease in -cell mass in type 2 diabetes
results primarily from increased -cell death via apoptosis
(40,41), and formation of toxic IAPP aggregates is thought
to be an important contributor to the progressive loss of
-cells in this disease (1,16,42). It remains unclear whether
aggregation of IAPP and amyloid formation is a cause of
-cell loss or simply a marker of -cell death and dysfunc-
tion. Here, we show, using a human islet culture model,
that suppression of human IAPP expression inhibits islet
amyloid formation and enhances survival and function of
islet -cells. These findings provide direct evidence to
support the hypothesis that aggregation of IAPP leads to
-cell death in human islets in situ and point to inhibition
of IAPP expression as a potential therapeutic target in type
2 diabetes.
Islet amyloid may take years to form in the type 2
diabetic pancreas, but recent reports have described rapid
amyloid formation in islets of human IAPP transgenic mice
after prolonged culture or after transplantation (23,34,43)
and after transplantation of human islets into immune-
deficient mice (43). Here, we show that human islets,
when cultured in moderately elevated glucose concentra-
tions, rapidly develop amyloid associated with cell death.
FIG. 6. siRNA-mediated suppression of human IAPP expression increases -cell–to–-cell ratio in cultured human islets. A: Double immunostain-
ing for insulin (green) and glucagon (red) of paraffin-embedded sections (5 m) of human islets preculture (d 0) and after 10-day culture with
or without transduction with Ad-hProIAPP-siRNA (MOI 20) or Ad-Cont-siRNA (as control for adenoviral toxicity and siRNA nonspecific effects).
The number of insulin immunopositive cells and intensity of immunostaining appeared to be reduced after 10-day culture but was preserved in
Ad-hProIAPP-siRNA–transduced islets. B: Quantification of insulin- and glucagon-positive cells in transduced and nontransduced cultured human
islets. Results are presented as -cell–to–-cell ratio from at least 30 islets per condition from each human islet preparation. Note the decrease
in the ratio of - to -cells in cultured human islets and its restoration after transduction with Ad-hProIAPP-siRNA. Transduction with
Ad-Cont-siRNA did not have any significant effect on -cell–to–-cell ratio. Data are expressed as means  SE of three independent experiments
(P < 0.01, one-way ANOVA). (Please see http://dx.doi.org/10.2337/db08-0485 for a high-quality digital representation of this figure.)
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Taken together, these findings raise the possibility that
rapid amyloid formation might be a contributing factor to
-cell demise during culture or after transplant. Targeting
IAPP expression might therefore have value to improve
viability of human islets during pretransplant culture and
after transplantation.
Although cultured human islets provide a useful model
for studies on islet amyloid formation and -cell death,
this experimental model may not completely mimic the
conditions in the type 2 diabetic human pancreas. One
possible explanation underlying the rapid amyloid forma-
tion in cultured human islets is that clearance of proIAPP
from the islet after its secretion may be impaired in
isolated islets, occurring via diffusion rather than perfu-
sion of the islet vasculature as occurs in vivo. Prolonged
residence in the islet after secretion from -cells may then
allow more time for IAPP to accumulate and aggregate. A
second possibility is that processing of the IAPP precur-
sor, proIAPP, may become impaired in islets during pro-
longed culture, manifest as accumulation of an NH2-
terminally extended proIAPP processing intermediate (see
Fig. 2 and ref. 20). We and others have recently demon-
strated that impaired NH2-terminal processing of proIAPP
leads to fibril formation and cell death in vitro (22,23). It is
possible that the culture conditions used, including high
glucose (11 mmol/l), induce impaired processing of
proIAPP, leading to accumulation of misfolded forms of
the precursor in the ER and other intracellular compart-
ments. Alternatively, secretion of incompletely processed
proIAPP may lead to its binding to heparan sulfate proteo-
glycans (21) and its accumulation in the intracellular
space. Whether the mechanism underlying rapid amyloid
formation in cultured human islets resembles that in type
2 diabetes remains to be determined.
The proportion of TUNEL-positive cells after 10-day
culture was 20% of the total number of islet cells and
reduced to10% by adenoviral expression of human IAPP
siRNA. This high proportion of TUNEL-positive cells is
similar to a previous report (44) and suggests a high
incidence of cell death occurring in human islets during
normal culture conditions. In vivo, apoptotic -cells are
rapidly cleared by macrophages, and cells are only tran-
siently TUNEL positive, but in vitro apoptotic cells are not
cleared and therefore likely remain TUNEL positive for
much longer. Therefore, the number of TUNEL-positive
islet cells at day 10 of culture is probably reflective of
cumulative cell death over the preceding few days.
Recent studies suggest that IAPP-induced cell toxicity is
mediated not by amyloid per se but primarily by smaller
aggregates of IAPP, termed protofibrils or oligomers (12–
14,22,25,45,46). These studies raise the important consid-
eration that any therapeutic approach targeting IAPP and
amyloid formation should not increase the proportion of
these smaller toxic species. Another recently proposed
mechanism suggests that growth of IAPP-derived fibrils at
the cell membrane induces cytotoxicity (47). Because
inhibition of IAPP expression is upstream of the earliest
events in IAPP aggregation, our siRNA approach is pre-
dicted to inhibit the formation of both oligomers and
amyloid fibrils. The marked improvements in cell viability
that we observed point to the validity of IAPP synthesis as
a target for preservation of human islet cells.
Given the potential toxicity of adenoviral infection of
islet cells and the potential for nonspecific effects of siRNA
expression, it is important in any such study to include
appropriate controls. In this study, we also assessed
amyloid formation and islet cell toxicity in cells trans-
duced with the same MOI of adenovirus expressing a
random siRNA, and we observed no differences in amyloid
area, proportion of TUNEL-positive cells, insulin content,
and secretion. This finding strongly suggests that the
beneficial impact of adenoviral expression of human
proIAPP siRNA in islets cells was due to siRNA-mediated
inhibition of IAPP expression.
In summary, using cultured human islets as an ex vivo
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FIG. 7. siRNA-mediated inhibition of proIAPP synthesis enhances
-cell function in cultured human islets. GSIS was assessed in non-
transduced and Ad-hProIAPP-siRNA (or Ad-Cont-siRNA) transduced
human islets (MOI 20) after 10-day culture in CMRL (11.1 mmol/l
glucose). Islets were incubated with KRBB (1.67 mmol/l glucose) for
1 h followed by 1-h incubation in the same condition (basal release) or
with KRBB containing 16.7 mmol/l glucose (stimulated insulin release).
Insulin secretion (A) and islet insulin content (B) were measured by
an enzyme-linked immunosorbent assay that measures mature insulin.
Transduced human islets had higher insulin content and enhanced
glucose response compared with nontransduced cultured islets. Re-
sults are expressed as means  SE of three independent experiments
(P < 0.01, one-way ANOVA).
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model of rapid islet amyloid formation, we showed that
siRNA-mediated inhibition of human (pro)IAPP synthesis
effectively prevents amyloid formation and enhances hu-
man -cell survival and function. Assuming appropriate
vehicles for delivery of siRNA to islets in vivo may become
available in the future, this approach has therapeutic
potential for preservation of -cell mass in type 2 diabetes.
In the meantime, targeting proIAPP expression in human
islets ex vivo has potential immediate application in
enhancing preculture transplant of human islets.
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